Article
Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial.
JAMA network open - 2 Mar 2026
Eadon Michael T, Cavanaugh Kerri L, She Lilin, Steen-Burrell Kady-Ann, Mohottige Dinushika, Nadkarni Girish N, Kitzman Heather, Chakraborty Hrishikesh, Empey Philip E, Limdi Nita A, Singh Rajbir, Beasley Cherry Maynor, Parker Alexander S, Cicali Emily J, Ramos Michelle A, Clermont Sabrina, Dodgen Leilani, Elwood Erica N, Robinson Mimsie, Umeukeje Ebele M, Garcia Ortega Abraham, Shroff Nandini, Rosenman Marc B, Nguyen Khoa A, Volpi Simona, Rider Renee, Dexter Paul R, Skaar Todd C, Peterson Josh F, Cavallari Larisa H, Johnson Julie A, Wyatt Christina M, Orlando Lori A, Cooper-DeHoff Rhonda M, Horowitz Carol R
Abstract excerpt
Importance: Apolipoprotein L1 locus (APOL1) high-risk alleles are associated with incidence of chronic kidney disease (CKD) among people with African ancestry. Few studies have examined the effect of genetic return of results on blood pressure (BP) management and control. Objective: To determine whether providing APOL1 high-risk genotype results to people with hypertension and their clinicians would reduce...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
